CRANBURY, N.J., Oct. 24, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase II clinical trial of CPI-613 for the treatment of relapsed or refractory small cell lung cancer (SCLC) patients. CPI-613 is the company’s lead Altered Energy Metabolism Directed (AEMD) drug candidate, which is designed to disrupt the altered energy-production pathways in cancer cells.
Help employers find you! Check out all the jobs and post your resume.
